View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Clinical Trials Analysis
April 5, 2021updated 16 Apr 2021 1:53pm

Japan accounts for 4.6% share of global clinical trial activity in 2020

Japan has accounted for a 4.6% share of the global clinical trials activity in 2020, registering a decrease when compared with the last ten-year average of a 10.5% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in Japan

Industry sponsored trials held a 76.6% share of all the clinical trials in Japan in 2020, when compared with the ten-year average of 45.8%. Non-industry sponsored trials accounted for a 23.4% share in 2020 as against the average of 54.2% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in Japan

Oncology was the leading therapy area for industry sponsored clinical trials in Japan in 2020 with a 33.7% share, as against a five-year average of 30.0% and a ten-year average of 28.0%.

Central Nervous System held an 11.6% share in 2020, over a five-year average of 11.8% and a ten-year average of 12.3%.

Infectious Disease held a 9.8% share in 2020, compared to a five-year average of 5.6% and a ten-year average of 6.4%. Metabolic Disorders held an 8.4% share in 2020, as against a five-year average of 10.9% and a ten-year average of 11.9%.

Dermatology held a 5.9% share, over a five-year average of 4.7% and a ten-year average of 3.8%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in Japan

Oncology was the leading therapy area for non-industry sponsored clinical trials in Japan in 2020 with a 40.9% share, as against a five-year average of 30.9% and a ten-year average of 35.8%.

Infectious Disease held a 14.8% share in 2020, over a five-year average of 8.3% and a ten-year average of 7.5%.

Central Nervous System held a 14.3% share in 2020, compared to a five-year average of 14.3% and a ten-year average of 11.8%. Gastrointestinal held an 8.9% share in 2020, as against a five-year average of 12.3% and a ten-year average of 10.0%.

Cardiovascular held an 8.0% share, over a five-year average of 9.9% and a ten-year average of 11.4%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead industry sponsored clinical trials in Japan in 2020

Phase II trials held a 34.6% share of industry sponsored clinical trials in Japan in 2020, over a five-year average of 41.4% and a ten-year average of 37.6%.

Phase III trials held a 31.4% share in 2020, as against a five-year average of 29.3% and a ten-year average of 32.4%. Phase IV trials held a 17.5% share in 2020, compared to a five-year average of 14.8% and a ten-year average of 14.3%.

Phase I trials held a 16.5% share in 2020, over a five-year average of 14.6% and a ten-year average of 15.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead non-industry sponsored clinical trials in Japan in 2020

Phase II trials held a 66.7% share of non-industry sponsored clinical trials in Japan in 2020, over a five-year average of 75.6% and a ten-year average of 74.9%.

Phase III trials held a 13.9% share in 2020, as against a five-year average of 4.9% and a ten-year average of 5.5%. Phase IV trials held a 12.2% share, compared to a five-year average of 13.0% and a ten-year average of 12.3%.

Phase I held a 7.2% share in 2020, over a five-year average of 6.6% and a ten-year average of 7.4%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU